These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 21991951)

  • 1. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS;
    N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
    N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
    N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
    Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS;
    Mult Scler; 2013 Sep; 19(10):1310-9. PubMed ID: 23447359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
    Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW;
    Neurology; 2012 Jun; 78(23):1877-85. PubMed ID: 22622860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.